check_circleStudy Completed

Prevention of venous thromboembolism after MOS

Bayer Identifier:

12606

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2010-020237-70

EU CT Number:

Not Available
BAY59-7939, Interaction Study with Fluconazole

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 45 Years
  • -

  • -

Trial summary

Enrollment Goal
13
Trial Dates
June 2010 - June 2010
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer HealthCareWuppertal, 42096, Germany

Trial design

Randomized, open label, 2-fold cross-over study to investigate the influence of multiple doses of 400 mg fluconazole on safety, tolerability, and pharmacokinetics of a single oral dose of 20 mg rivaroxaban in healthy male subjects
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.